Name
Future Management for High Blood Pressure
Description

This plenary evaluates the evidence for renal denervation as a treatment option for resistant hypertension and compares emerging pharmacologic agents, including aprocitentan and baxdrostat, with existing therapeutic options.

Learning Objectives
At the conclusion of this session, participants will be able to:

  • Evaluate the evidence for renal denervation as a treatment option for resistant hypertension.
  • Compare emerging pharmacologic agents, including aprocitentan and baxdrostat, with existing therapeutic options.
Speakers
Dr. Sheldon Tobe Professor of Medicine at the University of Toronto and the Northern Ontario School of Medicine, and Staff Nephrologist Sunnybrook Health Sciences Centre Sunnybrook Health Sciences Centre
Date & Time
Saturday, November 7, 2026, 1:00 PM - 2:00 PM
Location Name
Grand Ballroom - Salons A-D